Mankind Pharma to buy 70% of Belgium’s ACTx for €48 million
In short
Mankind Pharma plans to buy 70% of Belgium’s ACTx for €48 million. The deal would give it access to experimental cancer treatments, including work on blood and lung cancers.
This matters because it expands the company’s research reach outside India and into advanced cancer therapy. The final closing date and any approval steps are not stated in the available reporting.
What the reporting says
Mankind Pharma will acquire a 70% stake in Belgium-based ACTx for €48 million, giving it access to experimental treatments for blood and lung cancers. The deal is described as a step into next-generation CAR-T cancer therapies and part of the company’s global research ambitions. The reporting does not state when the transaction will close or whether any regulatory approvals are still pending.
Why it matters
Mankind Pharma will acquire a 70% stake in Belgium's ACTx for €48 million, according to the source summaries. The deal gives the Indian drugmaker access to experimental treatments targeting blood and lung cancers and is framed as an entry into next-generation CAR-T therapies. The reporting does not state the closing timeline, whether approvals are required, or how the acquisition will affect finances.